Cordlife Group Limited
Cordlife Group Limited
Your view on CLIFF
Overview
What the company does, where it operates, and who runs it.
About Cordlife Group Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Xiaoling Chen
- Headquarters
- A’Posh Bizhub, Singapore, SG
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Xiaoling Chen
- Headquarters
- A’Posh Bizhub, Singapore, SG
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. The company operates through two segments, Banking and Diagnostics.
It provides cord blood, cord lining, and cord tissue banking services comprising processing and storage of stem cells; and non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening, and newborn genetic screening services.
The company also offers preimplantation genetic screening, endometrial receptivity test, paediatric allergen test, and genetic talent test services, as well as moms up, a mobile app for pregnancy and parenting resources. In addition, it provides management, marketing, and property investment services.
Cordlife Group Limited was incorporated in 2001 and is headquartered in Singapore.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Cordlife Group Limited, and the rating behind it. CLIFF last traded at $0.07; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cordlife Group Limited. Starting points for Cordlife Group Limited: EPS -$0.04, beta 0.70 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cordlife Group Limited. Cordlife Group Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cordlife Group Limited. Trailing twelve-month EPS for Cordlife Group Limited stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cordlife Group Limited. Cordlife Group Limited has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cordlife Group Limited valued side by side against its closest peers. Cordlife Group Limited is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Cordlife Group Limited, and how their positions are changing. At a $17.7M market value, institutional positions materially move Cordlife Group Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Cordlife Group Limited executives and directors. Shares of Cordlife Group Limited have traded between $0.07 and $0.17 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cordlife Group Limited. Cordlife Group Limited is a $17.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cordlife Group Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cordlife Group Limited. Coverage tracks Cordlife Group Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.